iRadimed Corporation

Welcome to the Eratomed Corporation First Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode, and at the end of the call, we will conduct a question-and-answer session. As a reminder, this call is being recorded today, April 29, 2022, and contains time-sensitive information that is accurate only as of today. Earlier, Aratamed released its financial results for the first quarter of 2022. A copy of this press release announcing the company's earnings is available under the heading News on their website at aratamed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8K and can be found at sec.gov. This call is being broadcast live over the Internet on the company's website at aradamed.com, and a replay of the call will be available on the website for the next 90 days. Some of the information to be furnished in today's session will constitute four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Four looking statements are those focused on the future performance, results, plans, and events and may include the company's expected future results. Aratamed reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risk and uncertainties that may affect the company's business, please see the risk factors section of the company's most recent reports filed with the Securities and Exchange Commission, which again may be obtained for free from the SEC's website at sec.gov. I would now like to turn the call over to Roger Susi, President and Chief Executive Officer of Aratamad Corporation. Mr. Susi.

Thanks, Operator, and good morning, and thank you all for joining us on the call this morning. Aratamad had another very good quarter of revenue and earnings growth, as was reported in this morning's release. The trend of strong demand for our products remains intact, and thus we feel very good about the coming quarters as well. As reported in this morning's release, first quarter revenue was $12.3 million, nearly a 34% increase over the first quarter last year. Non-GAAP earnings were $0.22, or 69%, over Q1 2021. I'm very pleased with these results and the strong start our company has had in 2022. Our sales team continues to perform well, increasingly driving customer demand for our products. Total Q1 bookings remained at record levels, coming in 52% higher than Q1 last year. Strong demand for our products has given us additional visibility through a growing backlog, which increased from its year-end level of 10.9 million. Our engineering and regulatory teams continue to work closely on obtaining 510 clearance for our next generation IV pump, which has been branded the Meridian 3870. We continue working diligently to meet our timelines for the second half of this year. And while there is still much to complete, we are committed to doing everything we can do to achieve our goal. Regarding our new ferromagnetic detection system. We plan to install our first placements this quarter with a growing number of installations from that point on. As I have said in the past, we feel very good about where we are with this product and believe that we have a technologically superior system compared to the others already in the field. Regarding our financial guidance, we have considered the booking trends, and the added visibility we have through growing backlog. We've also considered the macro risks associated with supply chain and feel confident in increasing our full year expectations. Those supply issues are a near daily consideration at some level, and supply instability is not a familiar norm the world over. As we have the means and tenacity to find workaround solutions as necessary, we have comfort that we can continue to make shipments without material delay. Considering Q1 with an eye on sales levels and deal count, we now expect full year 2022 revenue of 52.5 million to 53.2 million with gap earnings of 89 cents to 95 cents and non-gap earnings of 96 cents to $1.03. Additionally, The second quarter this year, we expect revenue of $12.5 to $12.7 million, with gap earnings of $0.21 to $0.23 and non-gap earnings of $0.23 to $0.25. Now, before turning the call over, I'd like to address the executive transition that we announced yesterday afternoon. As disclosed, Chris Scott has resigned from the company effective May 27th to pursue other opportunities. Over the next 30 days, he'll be focused on a smooth transition of financial responsibilities to Matt Garner, who will serve as interim CFO while we go through a search process. Chris has been a valued partner to me and the rest of the organization during his eight-plus years here. He has supported the company every step of the way and will be missed. Sorry as we are to see him go, he leaves a very capable finance team and the company in good shape. which the finance team will now be led by Matt. This has been the situation for the last several years. I'm confident in Matt's abilities to maintain the quality and integrity of our financial information during this search process. And now I'd like to turn the call over to Matt so he can introduce himself and to review the financial results of the quarter.

Matt. Thank you, Roger, and good morning, everyone. Before summarizing the financial results, I'd like to spend a moment and introduce myself. I began with ArataMed in February 2014 as the assistant controller, and in 2020 was elevated to the controller role. Over these last eight years with ArataMed, I've developed a deep understanding of the company and its culture. Overall, I have 15 years of experience within the medical equipment industry, including seven years at Rogers' former company. I also hold a bachelor's degree in accounting from Southern New Hampshire University. I am thankful for the opportunity to serve as the company's interim CFO and look forward to interfacing with you while the search proceeds. Now on to the financial summary. As in the past, I will be discussing these results on a GAAP basis as well as on a non-GAAP basis. You can find a description of our non-GAAP operating measures in this morning's earnings release. You can also find a reconciliation of these non-GAAP measures to the nearest GAAP measure on the last page of today's release. As reported earlier this morning, first quarter 2022 revenue was $12.3 million, an increase of 33.5% compared to the first quarter of 2021. Revenue from domestic sales increased 37.2% to $10 million, and revenue from international sales increased 19.5% to $2.3 million. Overall, domestic revenue accounted for 81.1% of total revenue for Q1 2022, compared to 78.8% for Q1 of 2021. Device revenue increased 38.8% to $8.5 million. This was driven by a 99.5% increase in monitor revenue resulting from continued customer acceptance and win rates. The average selling price of our MRI compatible IV fusion pump system during the first quarter 2022 was approximately $33,800 compared to approximately $32,700 for the first quarter of 2021. This increase relates to higher domestic unit sales partially offset by an unfavorable product sales mix. The average selling price of our MRI compatible patient vital signs monitoring system during the first quarter of 2022 was approximately $46,800 compared to approximately $38,300 for the same period in 2021. This increase relates to higher domestic unit sales and price increases that we began implementing during the second half of 2021. Revenue from disposables and service increased 25.9% to 3.3 million for the first quarter of 2022. And revenue from our maintenance contracts was consistent at a half a million dollars for both periods. Gross margin was 76.2% for the 2022 quarter compared to 76.6% for the 2021 quarter. The decrease in gross margin percent is primarily due to unfavorable labor and overhead expenses, partially offset by higher domestic sales. While the supply chain remains challenging, we continue to believe that any negative impact from higher costs will likely be limited and partially offset by higher levels of unit production, resulting in gross margins that are consistent with our historical ranges. Operating expenses were 6.3 million or 51.2% of revenue compared to 5.3 million or approximately 57.3% of revenue for the first quarter of 2021. On a dollar basis, this increase is primarily due to higher sales commissions, payroll and benefit costs, sales activity expenses, and engineering costs for prototyping and design. As a result, Income from operations grew 73% to $3.1 million for the 2022 quarter. We recognize a tax expense during the first quarter 2022 of approximately $573,000, resulting in an effective tax rate of 18.7% compared to a tax expense of approximately $384,000 in the 2021 quarter. This increase is due to higher taxable income partially offset by benefits associated with stock compensation and research and development credits. On a GAAP basis, net income was 20 cents per share compared to 11 cents for the 2021 quarter. On a non-GAAP basis, adjusted income was 22 cents per diluted share for the 2022 quarter compared to 13 cents for the first quarter 2021. Cash from operations grew to $1.4 million for the three months ended March 31, 2022, from $0.9 million for the same period in 2021. For the three months ended March 31, 2022 and 2021, our free cash flow, a non-GAAP measure, was $1.2 million and $0.8 million, respectively. And with that, I will turn the call over for questions. Operator?